[{"address1": "680 West Nye Lane", "address2": "Suite 204", "city": "Carson City", "state": "NV", "zip": "89703", "country": "United States", "phone": "775 888 3162", "website": "https://bioviepharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease. The company develops BIV201 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.", "fullTimeEmployees": 14, "companyOfficers": [{"maxAge": 1, "name": "Mr. Cuong Viet  Do M.B.A.", "age": 57, "title": "President, CEO & Director", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 618000, "exercisedValue": 0, "unexercisedValue": 97254}, {"maxAge": 1, "name": "Ms. Joanne Wendy Kim CPA", "age": 68, "title": "CFO, Treasurer & Corporate Secretary", "yearBorn": 1955, "fiscalYear": 2024, "totalPay": 270000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Joseph M. Palumbo M.D.", "age": 63, "title": "Executive VP of R&D and Chief Medical Officer", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 560000, "exercisedValue": 0, "unexercisedValue": 19991}, {"maxAge": 1, "name": "Mr. Clarence N. Ahlem", "age": 68, "title": "Senior Vice President of Operations", "yearBorn": 1955, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Penelope  Markham Ph.D.", "age": 57, "title": "Senior Vice President of Liver Disease Program", "yearBorn": 1966, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Denise  Smith", "title": "Senior Vice President of Manufacturing & Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Christopher L. Reading Ph.D.", "age": 75, "title": "Senior Vice President of Alzheimer's Disease Program", "yearBorn": 1948, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "maxAge": 86400, "priceHint": 4, "previousClose": 2.25, "open": 2.2, "dayLow": 2.07, "dayHigh": 2.32, "regularMarketPreviousClose": 2.25, "regularMarketOpen": 2.2, "regularMarketDayLow": 2.07, "regularMarketDayHigh": 2.32, "beta": 0.902, "forwardPE": -0.48299325, "volume": 1047658, "regularMarketVolume": 1047658, "averageVolume": 6231708, "averageVolume10days": 1271390, "averageDailyVolume10Day": 1271390, "bid": 1.65, "ask": 2.68, "bidSize": 200, "askSize": 200, "marketCap": 37846268, "fiftyTwoWeekLow": 1.04, "fiftyTwoWeekHigh": 33.1, "fiftyDayAverage": 2.7013, "twoHundredDayAverage": 3.631975, "currency": "USD", "enterpriseValue": 7486111, "floatShares": 4715059, "sharesOutstanding": 17768200, "sharesShort": 1921578, "sharesShortPriorMonth": 383126, "sharesShortPreviousMonthDate": 1727654400, "dateShortInterest": 1730332800, "sharesPercentSharesOut": 0.1082, "heldPercentInsiders": 0.13692, "heldPercentInstitutions": 0.09989, "shortRatio": 0.15, "shortPercentOfFloat": 0.1252, "impliedSharesOutstanding": 17768200, "bookValue": 2.505, "priceToBook": 0.8502994, "lastFiscalYearEnd": 1719705600, "nextFiscalYearEnd": 1751241600, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -33006956, "trailingEps": -5.08, "forwardEps": -4.41, "lastSplitFactor": "1:10", "lastSplitDate": 1722902400, "enterpriseToEbitda": -0.234, "52WeekChange": -0.83576643, "SandP52WeekChange": 0.2729931, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "BIVI", "underlyingSymbol": "BIVI", "shortName": "BioVie Inc.", "longName": "BioVie Inc.", "firstTradeDateEpochUtc": 1600435800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "eb7eacbe-6abc-3b57-b586-2bc16fc1c3b3", "messageBoardId": "finmb_242387715", "gmtOffSetMilliseconds": -18000000, "currentPrice": 2.13, "targetHighPrice": 5.0, "targetLowPrice": 5.0, "targetMeanPrice": 5.0, "targetMedianPrice": 5.0, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "totalCash": 23843798, "totalCashPerShare": 3.007, "ebitda": -31950208, "totalDebt": 6111447, "quickRatio": 2.55, "currentRatio": 2.571, "debtToEquity": 39.413, "returnOnAssets": -0.66693, "returnOnEquity": -2.0825999, "freeCashflow": -18778568, "operatingCashflow": -27945024, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-12-28"}]